id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ihlr-18967	Podgorny, Andrew E.	Supporting the Rationale Behind the Hatch-Waxman Act and Patent Law: How Reverse Payment Settlements Under FTC v. Actavis, Inc. Can Be Procompetitive	2015	48	.pdf	application/pdf	15693	715	51	As a result of Actavis, pioneer drug manufacturers may allocate more resources into developing new active ingredients as opposed to updating formulas of old products.139 As one empirical study, analyzing what type of drug patents get challenged most frequently under the Paragraph IV route, suggests, generic companies more often challenge pioneer drugs using a new formulation as compared to pioneer drugs containing a new active ingredient.140 By focusing on new active ingredients, there is a lower risk of patent litigation because a generic company is less likely to challenge the patent’s validity. With all that is considered, pioneer drug manufacturers who input more resources into new active ingredients will likely have an increased chance, albeit a small increase, of avoiding patent litigation while also providing socially valuable research and development.141 Accordingly, the policy interests of the Hatch-Waxman Act and patent law are supported as new research will be completed, resulting in new drug development.	cache/ihlr-18967.pdf	txt/ihlr-18967.txt